Preface: The K-Bio Development Strategy Can No Longer Be Delayed

Part 1: Next Chip War, Biowar

Chapter 1: Biowarfare, the Trigger Has Been Pulled
-The unleashed US bio-hegemony
-Europe's pursuit intensifies
China's biotech boom, targeting cutting-edge industries

Chapter 2: The Absolute Powerhouse, the United States
The world's largest market, the bio market, is also moving.
-The 'powerhouse' that monopolizes half of the global top 10

Chapter 3: America's Rival Europe
- Challenger of Bio's 'Pax Americana'
-Novo Nordisk, the gold mine for obesity treatment
Lonza Dominates the Global CDMO Industry
-Vaccine powerhouses who led the way to ending COVID-19

Chapter 4: Asia Building New Technologies
-“I will catch America” China’s growing size
-Moonshot 'Game Changer' Japan
-India, the world's pharmaceutical factory
Southeast Asia Targets the Niche Market of Endemic Disease Eradication

Chapter 5: K-Bio in Pursuit of Hegemony
"Korea is too small": Shifting focus from domestic demand to overseas markets
-Large companies rushing into next-generation food
Launch of the National Bio-Pharmaceutical Commission: Policy Speed ​​Battle

Chapter 6: Global giants join the fray
Big tech merging with bio
- A bold challenge for traditional industries
[Interview] Patrick Hoever, President of Novartis International: "Korea's talent potential is enormous...We will become a biopowerhouse within five years."
[Interview] Kim Heung-yeol, Director of the Korea Research Institute of Bioscience and Biotechnology: "Cooperative ecosystems and digital transformation are key to K-bio's success."

Part 2: Customized Bios Rise

Chapter 1: Digital Bio Entering Everyday Life
Digital Health Dominates CES 2025
The Evolution of 'MedTech' Beyond Time and Space
-Faster and more accurate diagnostic AI
Wearable medical device 'Quantum Jump'
"Games are also medicine": The world of digital therapeutics

Chapter 2: The Dream Bio Proliferated by Data
Human Digital Twin: A Technology of Imagination Now a Reality
AI doctors are coming… the era of surgical robots
-Rush to capture niche markets with treatments
Global Big Deals Accelerate, Big Pharma Expands Market Share

Part 3: Why K-Bio?

Chapter 1: Low Growth vs. Securing a Growth Engine: Korea at a Crossroads
-Korea, where traditional manufacturing is the answer
-Bio is now changing the economic landscape.

Chapter 2: Korea's Growth Path Depends on Bio
-Quantitative growth from generics to biotechnology
A frog in a well on the world stage... Competitiveness that even China lags behind
-Bio is the only solution to securing a second Samsung Electronics.
[Interview] Kim Min-ji, CEO of Crossborder Partners: "K-Bio Needs to Strengthen Global Networking"
[Interview] Kim Ji-soo and Bae Jin-won, Research Fellows at the Korea Institute for Industrial Economics & Trade: "Building an Asian Supercluster After SMEs Build Competitiveness"

Part 4: Bio-Hegemony Victory Strategy

Chapter 1: Velocity - Data Big Bang, Industrial Speed ​​Wars
Let's build the world's first government-certified data exchange.
-The 'Big 5' hospitals transform into startup midwives.
[Interview] Professor Baek Min-kyung of Seoul National University's Department of Biotechnology: "Spurring Protein Research...Taking on AI for New Drug Development"
[Interview] John Halamka, CEO of Mayo Clinic Platform: "AI-Driven Hospitals Are Coming"
[Interview] Professor Kim Deok-ho of Johns Hopkins University School of Medicine: "Artificial organs can reduce clinical trials by 30%."

Chapter 2: Venture - Jackpot New Drug Gamble
Korea's version of "Bio Stargate"... Breakthrough in public-private partnerships in new drug development
"Bio One Asia": Korea Takes the Lead in Integrated Clinical Trials
-Establishment of the Basic Science Jackpot Fund and groundbreaking support for original technologies.
-The bottleneck in new drug launches is so severe that review staff must double.
[Interview] Hong Seok-myeong, Patent Office Examiner: "Introducing a Fast Track for National Strategic Technologies and Licensing"
[Interview] Thomas Vega, Founder of Augmental: "We Must Unleash Human Productivity and Economic Potential with 'Dream Technology' Digital Bio."
[Interview] Jo Joo-hee, Director of the Clinical Epidemiology Research Center at Samsung Medical Center: "The Widening Health Gap... We Need to Address Digital Medical Illiteracy."

Chapter 3: Value Boost - Expanding Bio Territory
Break through the petrochemical crisis by mandating the use of white biotechnology.
- Green bio-accelerator pedal by relaxing genetic regulations
-Breaking the slack in corporate finances, easing requirements for technology-specific listings.
Intensifying biosecurity battles… Expanding self-sufficiency in raw materials
[Interview] Yasushi Kajii, President and CEO of Takeda Pharmaceutical Company, "Our goal is to commercialize the world's first pluripotent stem cell therapy."
[Interview] Seung-gu Lee, Director of the Synthetic Biology Lab at the Korea Research Institute of Bioscience and Biotechnology: "Synthetic biology is a game changer in the advanced bio era, and its utilization is increasing."

Chapter 4: Vitality - Anti-Aging Power
Establishing a national cell bank to dominate the cell therapy market.
From a plastic surgery powerhouse to an anti-aging powerhouse, K-medical tourism is being upgraded.
[Interview] Lee Byeong-geon, Advisor at GI Innovation: "Fostering the Medical Tourism Industry with Anti-Aging Treatments"
[Interview] Kim Dong-ik, Professor Emeritus of Sungkyunkwan University School of Medicine: "Aiming for clinical trials of anti-aging treatments by 2028."
[Interview] Seungwook Cho, CEO of Moniscell: "Fat is like stem cells, and we need to leverage it for medical innovation."

References
People who helped

In the 21st century, whoever controls bio will control the world.

A new war that will define the 21st century has begun.
Following the 'chip war' surrounding semiconductors, a 'bio war' surrounding biotechnology is now fiercely unfolding around the world.
Biotechnology has emerged as a new key to hegemony, swaying both economic and military power, and competition among countries to dominate this field is intensifying.
The United States has placed biotechnology at the top of its national security strategy, and China has declared itself a bio powerhouse and is making large-scale, government-led investments.
The European Union has also begun to actively restructure its industry through bio-innovation.

Biotechnology not only affects human health and quality of life, but is also a next-generation core driving force for the future economy and national defense.
Vaccine development, gene therapy, synthetic biology, and bio-artificial intelligence are becoming new battlegrounds for international competition, and the country that dominates these technologies is likely to dominate the global leadership for decades to come.
This book clearly explores the essence of the fiercely unfolding biowar and coolly analyzes the international status and crisis facing South Korea.
Can Korea replicate its success in the IT and semiconductor industries in the bio industry? What's needed now is a practical and concrete strategy, including regulatory innovation, talent development, and the establishment of a global cooperative network.
This book presents realistic solutions for winning the fierce biowar and explores ways for Korea to become a leader in the era of bio-superiority.

The bio revolution begins just for you.

Advances in biotechnology are now moving beyond simple medical treatment and ushering in an era of personalized medicine.
Precision medicine based on individual genetic information, gene therapy optimized for specific diseases, and the development of personalized vaccines are driving widespread changes across the medical, healthcare, and food industries.
This book closely examines the economic and social transformations that the era of personalized biotechnology will bring.
The proliferation of personalized biotechnology requires a new industrial ecosystem.
Traditional mass production and standardized treatment methods no longer work.
Customized solutions that take into account an individual's genetic characteristics and living environment are emerging as mainstream, and comprehensive preparation is essential, including building data infrastructure, artificial intelligence analysis, regulatory innovation, and establishing ethical standards.
This book presents the strategies Korea needs to leap forward as a leading nation in this massive trend.
For K-Bio to become competitive on the global stage, it must go beyond simple technological development and restructure the entire social system.
We present a national vision to foster talent, innovate policies, and lead global standards in the era of personalized biotechnology.
It provides essential insights for those working in the biotechnology industry, as well as policy makers and general readers.

K-Bio's Winning Strategy for Hegemony

The strategy for winning the race for bio-superiority is not simple.
This book presents a practical roadmap for K-Bio to become a global leader, focusing on six key tasks.

First, we must establish a foundation for the growth of the bio industry through regulatory innovation.
Second, we must foster world-class startups and unicorn companies to enhance the dynamism of the industrial ecosystem.
Third, we must systematically cultivate and support global-level bio-specialized talent.
Fourth, we must actively build networks and partnerships targeting the global market.
Fifth, we must accelerate biotechnology innovation through research and development (R&D) investment and strategic support at the national level.
Sixth, we must promote convergence and innovation across industries to maximize synergy with other industries, such as bio, ICT, and artificial intelligence.
This book explains in detail how these strategies should be organically linked, thereby exploring ways for Korea to emerge as a true victor in the battle for bio-superiority.
Now is the time to go beyond mere survival and take the initiative.
A comprehensive innovation in technology, talent, markets, and systems is needed, and this book will serve as a compass for that innovation.